Market research
EPE.F Epizyme, Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 240M
- P/E ratio
- Not available
- Analyst target
- 11.14
- Dividend yield
- 0.0%
- Beta
- -0.42
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 240M
- P/E ratio
- Not available
- Analyst target
- 11.14
- Dividend yield
- 0.0%
- Beta
- -0.42
About
About Epizyme, Inc
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Research context
Epizyme, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EPE.F discussion.
5 years, 7 months ago
Epizyme, Inc is currently in a long term downtrend where the price is trading 27.0% below its 200 day moving average.
From a valuation standpoint, the stock is 95.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 55.6.
Epizyme, Inc's total revenue rose by 95.0% to $8M since the same quarter in the previous year.
Its net income has dropped by 17.4% to $-66M since the same quarter in the previous year.
Finally, its free cash flow fell by 49.8% to $-53M since the same quarter in the previous year.
Based on the above factors, Epizyme, Inc gets an overall score of 2/5.